---
title: "Fangzhou Raises HK$144.3 Million to Speed AI Chronic Disease Platform Expansion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274521626.md"
description: "Fangzhou Inc. has raised HK$144.3 million through the placement of 45,181,000 shares at HK$3.32 each, with plans to use 90% of the proceeds for the development of its AI-powered chronic disease management platform. The remaining 10% will be allocated for working capital. The company aims to enhance its growth in digital health and AI services. Currently, the stock holds a Hold rating with a price target of HK$3.00."
datetime: "2026-02-02T13:38:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274521626.md)
  - [en](https://longbridge.com/en/news/274521626.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274521626.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274521626.md) | [繁體中文](https://longbridge.com/zh-HK/news/274521626.md)


# Fangzhou Raises HK$144.3 Million to Speed AI Chronic Disease Platform Expansion

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Fangzhou Inc. ( (HK:6086) ) has shared an update.

Fangzhou Inc. has completed a placing of 45,181,000 existing shares at HK$3.32 per share to at least six independent investors, followed by a top-up subscription of an equal number of new shares by the vendor, resulting in the issuance of new shares representing about 3.26% of the enlarged share capital. The transaction raised net proceeds of approximately HK$144.3 million, of which around 90% will be deployed to accelerate development, infrastructure, talent recruitment, data capabilities and market rollout of its AI-powered chronic disease management platform, with the remaining 10% earmarked for working capital and general corporate purposes, strengthening Fangzhou’s growth trajectory in digital health and AI-enabled medical services.

The most recent analyst rating on (HK:6086) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Fangzhou Inc. stock, see the HK:6086 Stock Forecast page.

**More about Fangzhou Inc.**

Fangzhou Inc., listed in Hong Kong and incorporated in the Cayman Islands, operates in the healthcare technology space with a focus on AI-driven chronic disease management platforms that target underserved patient and physician segments.

**Average Trading Volume:** 16,993,805

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$3.66B

### Related Stocks

- [FANGZHOU JIANKE (06086.HK)](https://longbridge.com/en/quote/06086.HK.md)

## Related News & Research

- [Fangzhou Raises HK$150 Million in Share Placement to Accelerate AI-Powered Chronic Care Platform](https://longbridge.com/en/news/273783418.md)
- [Mindflair Portfolio Firm Stylus Accelerates AI Edtech Adoption in Schools](https://longbridge.com/en/news/278998413.md)
- [SysGroup Transfers Treasury Shares to AI Board Adviser, Updates Voting Rights](https://longbridge.com/en/news/279025337.md)
- [2 artificial intelligence (AI) stocks trading below their true value right now](https://longbridge.com/en/news/278939096.md)
- [AI agents are upending the company org chart](https://longbridge.com/en/news/278361704.md)